公开(公告)号：US20220202923A1

公开(公告)日：2022-06-30

申请号：US17554424

申请日：2021-12-17

Applicant: Pfizer Inc.

Inventor： Ye Che ,  Laurent Oliver Chorro ,  Robert George Konrad Donald ,  Matthew Curtis Griffor ,  Natalie Clare Silmon de Monerri

IPC: A61K39/108 ,  C07K14/245 ,  C07K16/12

Abstract: This disclosure relates to the design of E. coli mutated FimH polypeptides that result in improved biochemical properties and immunogenicity, compositions comprising such polypeptides, and uses thereof.

公开(公告)号：US20230000966A1

公开(公告)日：2023-01-05

申请号：US17772610

申请日：2020-10-28

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Ye Che ,  Wei Chen ,  Laurent Oliver Chorro ,  Ling Chu ,  Robert G.K. Donald ,  Matthew Curtis Griffor ,  Jianxin Gu ,  Zeqiang Guan ,  Jin-Hwan Kim ,  Srinivas Kodali ,  Scott Ellis Lomberk ,  Jason Arnold Lotvin ,  Nishith Merchant ,  Justin Keith Moran ,  Rosalind Pan ,  Avvari Krishna Prasad ,  Mark Edward Ruppen ,  Suddham Singh ,  David Robert Stead ,  Karen Kiyoko Takane

IPC: A61K39/108 ,  C07K14/245

Abstract: In one aspect, the invention relates to a polypeptide derived from E. coli and a fragment thereof, including compositions and methods thereof. Also disclosed herein are compositions that include a polypeptide derived from E. coli and a fragment thereof; and modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. In a further aspect, disclosed herein are mammalian host cells that include sequence(s) encoding a polypeptide derived from E. coli or fragments thereof.

公开(公告)号：US11629172B2

公开(公告)日：2023-04-18

申请号：US16721229

申请日：2019-12-19

Applicant: Pfizer Inc.

Inventor： Philip Ralph Dormitzer ,  Ye Che ,  Xiaoyuan Sherry Chi ,  Seungil Han ,  Kyle Paul Heim ,  Thomas Richard Jones ,  Yuhang Liu ,  Xiayang Qiu ,  Xinzhen Yang ,  Xiaojie Yao ,  Matthew Curtis Griffor ,  Jennifer Anne Nicki

IPC: C07K14/005 ,  A61K39/00

Abstract: The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least one introduced amino acid mutation relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.

公开(公告)号：US20200247853A1

公开(公告)日：2020-08-06

申请号：US16721229

申请日：2019-12-19

Applicant: Pfizer Inc.

Inventor： Philip Ralph Dormitzer ,  Ye Che ,  Xiaoyuan Sherry Chi ,  Seungil Han ,  Kyle Paul Heim ,  Thomas Richard Jones ,  Yuhang Liu ,  Xiayang Qiu ,  Xinzhen Yang ,  Xiaojie Yao ,  Matthew Curtis Griffor ,  Jennifer Anne Nicki

IPC: C07K14/005

Abstract: The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least one introduced amino acid mutation relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.